Topic Hub
43 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 43 of 43 clinical reviews.
A physician-reviewed guide to acarbose as a longevity drug, covering its mechanism, ITP mouse data, human trial results, dosing, side effects, and how it compares with rapamycin, metformin, NR, and NMN.
Read clinical reviewA clinician-reviewed guide to the most effective longevity interventions for adults over 50, covering hormone optimization, cognitive protection, strength training, metabolic health, and dementia-risk reduction with specific doses, trials, and guidelines.
Read clinical reviewA comprehensive clinical guide for adults over 65 covering hormone therapy, dementia prevention, muscle preservation, and longevity protocols backed by named trials and current guidelines.
Read clinical reviewA clinician-reviewed breakdown of senolytics, rapamycin, metformin, and biological age testing for longevity, what the current trial data actually supports and what remains experimental.
Read clinical reviewA physician-reviewed breakdown of berberine's longevity evidence alongside rapamycin, metformin, NR, and NMN. Real trial data, doses, and clinical context.
Read clinical reviewA clinically grounded guide to biological aging, covering epigenetic clocks, cellular senescence, mitochondrial dysfunction, sarcopenia, frailty, and evidence-based interventions with real trial data.
Read clinical reviewA physician-reviewed deep dive into cellular senescence, the biology of zombie cells, their role in frailty, sarcopenia, and mitochondrial dysfunction, plus the current evidence on senolytic and senomorphic interventions.
Read clinical reviewCompounded rapamycin for longevity typically costs $40, $150 per month out of pocket. Insurance rarely covers off-label use. Learn exact pricing tiers, pharmacy options, and how to verify legitimacy.
Read clinical reviewA detailed 2026 pricing guide for NMN supplements, compounded rapamycin, and other longevity-focused compounds, plus an honest look at what insurance will and will not cover for off-label use.
Read clinical reviewA clinical review of metformin, rapamycin, senolytics, and biological age testing for longevity in non-diabetic adults. Covers TAME trial evidence, dosing, risks, and who qualifies.
Read clinical reviewA clinical deep-dive into rapamycin, senolytics, metformin, and biological age testing for longevity. Evidence-based guidance on what works, what is experimental, and what healthy adults should know before taking any longevity drug.
Read clinical reviewA clinician-reviewed guide to frailty syndrome covering the Fried phenotype criteria, biological mechanisms including sarcopenia and mitochondrial dysfunction, and interventions supported by randomized trial data.
Read clinical reviewA physician-reviewed deep dive into GLP-1 receptor agonists and four companion longevity drugs used off-label: rapamycin, metformin, nicotinamide riboside, and NMN. Covers mechanisms, trial data, doses, and candidacy criteria.
Read clinical reviewA physician-reviewed deep dive into glucosamine as a longevity compound, plus the most current evidence on rapamycin, metformin, nicotinamide riboside, and NMN for healthy aging.
Read clinical reviewInflammaging is the chronic, low-grade inflammatory state that accelerates biological aging, drives cellular senescence, and raises the risk of cardiovascular disease, dementia, and frailty. Learn what the science says and what you can do about it.
Read clinical reviewA physician-reviewed guide to insurance coverage for off-label drug use, including rapamycin, NMN, GLP-1s, and compounded therapies. Understand your appeal rights, real costs, and clinical strategies to reduce out-of-pocket spending.
Read clinical reviewA clinician-reviewed guide to long-term metformin safety, covering lactic acidosis risk, B12 depletion, kidney thresholds, rapamycin monitoring, and senolytic trial signals.
Read clinical reviewA clinician-reviewed guide to longevity medicine for athletes over 40 and 50, covering TRT, GLP-1s, HGH peptides, HRT, cognitive protection, and dementia risk reduction backed by named trials and guidelines.
Read clinical reviewA physician-reviewed guide to the longevity interventions with the strongest clinical evidence, including GLP-1s, exercise, sleep, diet, biomarker testing, and hormone optimization.
Read clinical reviewA clinician-reviewed look at low-dose lithium, rapamycin, metformin, NR, and NMN as longevity agents. Covers mechanisms, doses, trial data, and safety considerations.
Read clinical reviewOff-label metformin prescribing for healthy adults as an anti-aging intervention rests on thin human evidence. The HealthRX Medical Team argues that until TAME reports, prescribing should follow metabolic indications, not a generalized aging signal.
Read clinical reviewA clinician-reviewed breakdown of metformin, rapamycin, NR, NMN, and glucosamine as off-label longevity agents. Covers mechanisms, trial data, doses, risks, and how to talk to your doctor.
Read clinical reviewA physician-reviewed guide to mild cognitive decline covering biological aging, cellular senescence, mitochondrial dysfunction, and frailty syndrome, with evidence-based interventions and dosing details.
Read clinical reviewMitochondrial dysfunction drives biological aging, frailty, sarcopenia, and cellular senescence. Learn the mechanisms, biomarkers, and evidence-based interventions clinicians use to slow or partially reverse mitochondrial decline.
Read clinical reviewA clinician-reviewed deep dive into NMN supplementation, how it compares to NR, metformin, rapamycin, and glucosamine, with real trial data, dosing protocols, and safety considerations.
Read clinical reviewA clinician-reviewed deep-dive into nicotinamide riboside (NR): how it raises NAD+, what human trials actually show, how it compares to NMN, rapamycin, metformin, and glucosamine, and what doses are supported by current evidence.
Read clinical reviewA clinician-reviewed guide to NMN and NR dosing, weekly rapamycin protocols, and off-label metformin dosing for longevity, with trial data and specific dose ranges for each compound.
Read clinical reviewA physician-reviewed comparison of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) for raising NAD+ levels, with a head-to-head look at rapamycin and metformin as longevity interventions. Includes trial data, dosing, and clinical decision guidance.
Read clinical reviewA physician-reviewed guide to off-label metformin dosing for longevity, covering evidence from TAME, ITP mouse data, rapamycin weekly protocols, and NMN/NR NAD+ precursor dosing, with inline citations to primary sources.
Read clinical reviewThe HealthRX Medical Team takes a position on off-label weekly rapamycin in healthy adults: the ITP mouse data and the PEARL trial are genuinely promising, but the gap between rodent lifespan extension and human longevity remains real. Here is how we actually use it in practice.
Read clinical reviewA rigorous side-by-side synthesis of PEARL (2024), RAP-4 (2025), Mannick 2018, and Kraig 2018 on rapamycin dosing, immune endpoints, biological-age proxies, and adverse effects in healthy aging adults.
Read clinical reviewA physician-reviewed guide to rapamycin, metformin, NR, NMN, and glucosamine as longevity interventions, mechanisms, trial data, doses, and clinical decision points.
Read clinical reviewA clinical deep-dive into rapamycin side effects, safety signals from senolytic and longevity trials, long-term metformin safety comparisons, and the lab monitoring schedule every off-label user needs.
Read clinical reviewA head-to-head comparison of rapamycin and metformin as longevity interventions, covering mechanisms, clinical trial data, dosing protocols, side-effect profiles, and how NR and NMN stack up as adjuncts.
Read clinical reviewA clinician-reviewed guide to rapamycin weekly dosing protocols for longevity, covering dose ranges, NMN/NR co-administration, off-label metformin stacking, and the evidence base behind each approach.
Read clinical reviewSarcopenia is the age-related loss of skeletal muscle mass and strength that drives frailty, falls, and early death. Learn what causes it, how it is diagnosed, and which interventions actually work.
Read clinical reviewA clinical review of safety signals from senolytic, rapamycin, and metformin trials. Covers adverse events, monitoring protocols, and what current evidence means for patients considering longevity-focused prescribing.
Read clinical reviewA clinician-reviewed deep dive into whether SGLT2 inhibitors like empagliflozin and dapagliflozin extend healthspan, how they compare to rapamycin, metformin, NR, and NMN, and what the current evidence supports for off-label longevity use.
Read clinical reviewA clinician-reviewed breakdown of whether healthy adults should use rapamycin for longevity, covering human trial data, dosing protocols, side-effect profiles, biological age testing, senolytics, and metformin as comparators.
Read clinical reviewSpermidine triggers autophagy, reduces cardiovascular risk, and may extend healthspan. Learn the evidence-backed doses, food sources, and how it compares to rapamycin, metformin, NR, and NMN.
Read clinical reviewIf a parent or sibling had dementia, your risk is real but not fixed. This clinically reviewed guide covers genetic risk, the critical hormone timing window, lifestyle evidence, and actionable steps for adults over 50 with a family history of dementia.
Read clinical reviewBiological age reflects how well your cells, organs, and epigenome are functioning, not how long you have been alive. Learn which tests measure it accurately, what the evidence says about slowing it, and which longevity drugs are ready for clinical use.
Read clinical reviewA clinician-reviewed guide to the blood tests, epigenetic clocks, and organ-function panels that measure biological age, plus what rapamycin, metformin, and senolytics actually do to those numbers.
Read clinical review